Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

[1]  K. Cooney,et al.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. , 2017, European urology.

[2]  S. Srivastava,et al.  Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2017, European urology.

[3]  S. Ambs,et al.  Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[4]  T. Rebbeck.  Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. , 2017, Seminars in radiation oncology.

[5]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[6]  T. Helleday.  PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Yeager,et al.  Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2 , 2015, GigaScience.

[8]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[9]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[10]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[11]  Maximilian E. R. Weiss,et al.  Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. , 2015, The Journal of molecular diagnostics : JMD.

[12]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[13]  S. Chanock,et al.  The new sequencer on the block: comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing , 2013, Human Genetics.

[14]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Easton,et al.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients , 2011, British Journal of Cancer.

[16]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[17]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[18]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[19]  S. Srivastava,et al.  The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. , 2009, Urologic oncology.

[20]  R. Kittles,et al.  Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men , 2009, Cancer Prevention Research.

[21]  D. Lubeck,et al.  Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? , 2002, The Journal of urology.

[22]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.